Three‑Gene ICD Score Predicts Colorectal Cancer Survival

Colorectal cancer remains a growing challenge

Colorectal cancer (CRC) is the world’s third‑most frequently diagnosed malignancy, adding roughly 1.9 million new cases every year—about one in ten of all cancers. Even more concerning is the sharp rise in incidence among younger adults in both developed and developing nations, breaking with historical age‑related trends. Biologically, CRC follows a multistep cascade of genetic alterations that fuels aggressive tumour growth, early relapse and distant metastasis. Although surgery, chemotherapy and newer targeted or immune‑based therapies have improved care, overall survival remains disappointingly low, especially for advanced‑stage disease. These realities highlight a critical gap: clinicians and researchers still lack robust biomarkers that can reliably predict prognosis, track treatment response and identify patients who might benefit from personalised therapies.

Why immunogenic cell death matters

“Immunogenic cell death reshapes the tumor immune microenvironment and activates the adaptive immune response.” – Wang P. et al.

Immunogenic cell death (ICD) occurs when dying tumor cells release danger signals that galvanize the immune system. Harnessing this process could improve responses to chemotherapy and immunotherapy, but its clinical relevance in CRC has been unclear.

Study goal

Researchers set out to build and validate an Immunogenic Cell Death‑related Risk Score (ICDRS) that can:

1. Predict overall survival in CRC.

2. Describe the tumor micro‑environment (TME).

3. Indicate likely sensitivity to chemotherapy drugs.

How the ICDRS was created

Key findings

1. Prognostic power

Patients with a high ICDRS had significantly shorter overall survival in both cohorts. The score remained an independent risk factor after adjustment for clinical variables.

2. A “hot‐but‐suppressed” micro‑environment

High‑risk tumors showed:

• Higher immune and stromal cell infiltration yet lower tumor purity.

• Enrichment of regulatory T cells and follicular helper T cells—cells linked to immune suppression.

• Activation of hypoxia, TGF‑β, apoptosis, and interferon‑gamma pathways.

These features suggest simultaneous immune activation and inhibition within the TME.

3. Distinct genomic landscape

High ICDRS tumors carried more copy‑number changes and frequent mutations in PTEN and COL27A1, hinting at greater genomic instability.

4. Drug‑response clues

The score correlated with predicted drug sensitivity:

• Low ICDRS ➜ greater sensitivity to agents such as the JAK2 inhibitor AZ960.

• High ICDRS ➜ greater sensitivity to the PLK1 inhibitor BI‑2536 and the ERK inhibitors ulixertinib/SCH772984.

These associations generate testable hypotheses for tailoring chemotherapy.

5. Functional evidence for NRP1

Silencing NRP1 in Caco‑2 CRC cells slowed proliferation, migration, and invasion, underscoring its pro‑tumor role.

Practical implications

Author perspective

“In conclusion, the ICDRS may serve as a reliable predictor of CRC prognosis and offers a promising direction for the clinical management of CRC patients.”

Limitations to remember

• Validation cohort was small (n = 50).

• Only overall survival was analyzed; treatment‑specific outcomes need study.

• Functional assays focused on NRP1; roles of CLMP and PLEKHO1 remain to be explored.

• Real‑world immunotherapy datasets were not available for testing.

Take‑home messages

1. ICDRS is a concise, three‑gene score that stratifies CRC survival.

2. High scores reveal an immune‑infiltrated yet suppressive TME and distinctive genomic changes.

3. Drug‑response correlations point to personalized chemotherapy options that merit experimental testing.

4. NRP1 functions as a driver of CRC cell aggressiveness, making it a potential therapeutic target.

Further multicenter, prospective studies will determine whether this signature can move from bench to bedside.

The translation of the preceding English text in Chinese:

结直肠癌仍是一项日益严峻的挑战

结直肠癌（CRC）是全球第三常见的恶性肿瘤，每年约新增 190 万例，占全部癌症的十分之一左右。更令人担忧的是，无论发达国家还是发展中国家，年轻成人的发病率正急剧攀升，打破了既往的年龄相关趋势。从生物学角度看，CRC 由多步骤的遗传变异级联驱动，导致肿瘤高度侵袭、早期复发及远处转移。尽管手术、化疗以及新兴的靶向与免疫疗法在一定程度上改善了治疗效果，整体生存率仍然不尽人意，尤其是晚期患者。这些现实凸显了一个关键空缺：临床医生和研究人员仍缺乏能够可靠预测预后、监测疗效并筛选个体化治疗受益人群的稳健生物标志物。

为什么免疫原性细胞死亡至关重要

“免疫原性细胞死亡可重塑肿瘤免疫微环境，并激活适应性免疫应答。” —— Wang P. 等

免疫原性细胞死亡（Immunogenic Cell Death, ICD）指肿瘤细胞死亡时释放“危险信号”，从而激活机体免疫系统。若能有效调动这一过程，或可增强化疗与免疫治疗的疗效，然而 ICD 在 CRC 中的临床意义尚未明晰。

研究目标

研究人员旨在构建并验证一个 免疫原性细胞死亡相关风险评分（ICDRS），用于：

1. 预测 CRC 患者的总体生存期；

2. 描述肿瘤微环境（TME）；

3. 指示对不同化疗药物的潜在敏感性。

ICDRS 的构建流程

关键发现

1. 预后预测能力

高 ICDRS 患者在训练与验证队列中总体生存期显著缩短；多因素分析亦确认其为独立危险因素。

2. “炽热但受抑制”的微环境

高风险肿瘤表现出：

• 免疫与基质细胞浸润升高，肿瘤纯度下降；

• 调节性 T 细胞、滤泡辅助性 T 细胞富集——提示免疫抑制；

• 缺氧、TGF‑β、凋亡与 IFN‑γ 通路激活。
  这些特征暗示 TME 同时存在免疫激活与抑制。

3. 独特的基因组景观

高 ICDRS 肿瘤具有更多拷贝数改变，并频繁突变 PTEN、COL27A1，提示基因组不稳定性更高。

4. 药物反应线索

• 低 ICDRS ➜ 可能对 JAK2 抑制剂 AZ960 更敏感；

• 高 ICDRS ➜ 可能对 PLK1 抑制剂 BI‑2536 以及 ERK 抑制剂 ulixertinib / SCH772984 更敏感。
  这些关联为化疗个体化提供可检验假设。

5. NRP1 的功能性证据

在 Caco‑2 CRC 细胞中沉默 NRP1 可抑制细胞增殖、迁移与侵袭，凸显其致瘤作用。

实践意义

作者总结

“综上，ICDRS 有望成为 CRC 预后可靠预测因子，并为临床管理提供新方向。”

研究局限

• 验证队列样本量小（n = 50）；

• 仅分析总体生存，未评估特定治疗结局；

• 功能实验聚焦 NRP1，未探及 CLMP、PLEKHO1；

• 缺乏真实世界免疫治疗数据验证。

核心要点回顾

• ICDRS：仅 3 个基因即可有效分层 CRC 生存风险；

• 高分组：免疫细胞浸润高却受抑制，伴独特基因组改变；

• 药物联系：评分提示差异化化疗敏感性，值得进一步试验；

• NRP1：驱动 CRC 细胞侵袭，具治疗潜力；

• 多中心、前瞻性研究将决定该特征能否真正走向临床应用。

Reference:

Pengcheng Wang, Wei Zhao, Linghong Guo, Hailei Cao